europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

EuropaBio draft response to the IIA on European Health Data Space

04/02/2021
FEEDBACK

EuropaBio draft response to the IIA on European Health Data Space

EuropaBio welcomes the European Commission’s plan to begin a discussion with stakeholders to develop the EHDS. Science is evolving fast and digital tools are accelerating our ability to conduct research. For the biotechnology industry, it is imperative quality data sets are collected and analysed, while protecting privacy and maintaining trust in how the data are used.

This initiative is an opportunity to accelerate innovations that will optimise diagnostic and treatments, increasing cost-effectiveness of healthcare systems. The EC should work with the MSs to develop/harmonise the infrastructures required to make this feasible. While the EHDS would enable sharing data among research organizations within the EU, this should not distract from also developing ways to effectively share such data with research organizations internationally. The success of the EHDS should be measured on its capacity to increase the competitiveness in the EU health sector and to create health innovations to the benefit of researchers, healthcare professionals and citizens.

Objective 1: Ensuring access, sharing and use of health data for healthcare delivery purposes
Access/exchange of health data for research, including secondary use health data, is today too limited in the EU. EuropaBio supports the intention to reduce fragmentation of legislation through introducing a governance framework to clarify the rules across the EU with regards to collecting, accessing, and analysing health data. As a research-based industry with a history of handling patient data, access to such quality data would accelerate the sector’s ability to develop innovations in diagnostics and therapeutics.

Interoperable data infrastructures should be developed. The value of such a network lies in the participation of all MSs and their ability to create such infrastructures. It will be equally important that all MSs, supported by the EC, maintain these to a common standard, including through appropriate funding mechanisms and sharing of relevant expertise. It will also be important to ensure local HCPs, as a key part of the system, are also trained on the harmonised system for entering and reading the data.

Furthermore, patient trust in sharing their data is key to the success of any initiative to harness data for healthcare purposes and research. Citizens must be assured their data is protected and only used for purposes within the principle of data altruism. Patients should remain owners of their data, and research entities should remain the owners of the data resulting from their research.

Objective 2: Fostering a genuine single market in digital health covering digital health services
Digital health services are an essential part of the Digital Single Market. Improved access to digital health services and products, including tele-health and mHealth, have the potential to greatly improve access to healthcare and patient ability to manage their own health. Other key initiatives, such as cross-border healthcare, are enabled by such digital infrastructures.

Objective 3: Enhancing the development, deployment, and application of trustworthy digital health products and services, including those incorporating AI in the field of health
The adoption of digital technologies in health, in particular AI, will play a critical role on how healthcare is delivered in the future. it will support process efficiencies, and help overcome staff shortages. Telemedicine can provide health expertise to remote areas of the EU, which may be distant from specialised HCPs or centres of excellence but can also serve in situations of emergency and, in general, simplify patients’ lives by avoiding unnecessary movements, speed up time to diagnoses and make available expertise.

In conclusion, EuropaBio is ready to serve as a constructive partner in exploring all options and co-designing a framework to ensure we can harness the data revolution in the interest of citizens, society, and the economy.

Download the file below to read the full feedback.

EuropaBio draft response to the IIA on European Health Data Space


Download
2021_02_H_O_EuropaBio-draft-response-to-the-IIA-on-European-Health-Data-SpaceDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

06/02/2023

Delivering Europe’s ambitions in rare disease


Read more
31/01/2023

EuropaBio’s 2022 Patient BioForum sets out recommendations to address the challenges of patients with unmet medical needs and calls for multi-stakeholder approach


Read more
17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more

Important links

  • Delivering Europe’s ambitions in rare disease
  • Joint Statement: The Data Act is a leap into the unknown

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies